{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:30:54Z","timestamp":1794562254748,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpet.2026.105005","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:32:03Z","timestamp":1786059123000},"page":"105005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ranolazine inhibits invasiveness of human breast cancer cells in combination with a tyrosine kinase inhibitor: Dose-dependent synergy"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3152-4627","authenticated-orcid":false,"given":"Ceren","family":"Sumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-8540","authenticated-orcid":false,"given":"Mustafa B.A.","family":"Djamgoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2026.105005_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jpet.2026.105005_bib2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jpet.2026.105005_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ctrv.2017.11.003","article-title":"Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies","volume":"62","author":"Lee","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jpet.2026.105005_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2019.02.006","article-title":"Recent therapeutic trends and promising targets in triple negative breast cancer","volume":"199","author":"Hwang","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpet.2026.105005_bib5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s10555-024-10195-6","article-title":"Electrical excitability of cancer cells-CELEX model updated","volume":"43","author":"Djamgoz","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jpet.2026.105005_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1574892811308010066","article-title":"Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic disease","volume":"8","author":"Djamgoz","year":"2013","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.jpet.2026.105005_bib7","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1002\/jcp.27399","article-title":"Colorectal cancer invasiveness in vitro: predominant contribution of neonatal Nav1.5 under normoxia and hypoxia","volume":"234","author":"Guzel","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jpet.2026.105005_bib8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4161\/chan.21910","article-title":"Voltage-gated sodium channels and metastatic disease","volume":"6","author":"Brackenbury","year":"2012","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.jpet.2026.105005_bib9","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1038\/s41388-024-03098-x","article-title":"A novel Nav1.5-dependent feedback mechanism driving glycolytic acidification in breast cancer metastasis","volume":"43","author":"Leslie","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.jpet.2026.105005_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-024-02622-w","article-title":"Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels","volume":"130","author":"Djamgoz","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpet.2026.105005_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpet.2026.105005_bib12","doi-asserted-by":"crossref","first-page":"23066","DOI":"10.1002\/jcp.28868","article-title":"Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: effects of combination with ranolazine","volume":"234","author":"Lee","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jpet.2026.105005_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10585-022-10166-7","article-title":"Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine","volume":"39","author":"Qiu","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jpet.2026.105005_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000501802","article-title":"Epidermal growth factor potentiates migration of MDA-MB 231 breast cancer cells by increasing NaV1.5 channel expression","volume":"97","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.jpet.2026.105005_bib15","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-05-0327","article-title":"Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis","volume":"11","author":"Fraser","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpet.2026.105005_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","article-title":"Evaluation of drug combination effect using a Bliss independence dose-response surface model","volume":"10","author":"Liu","year":"2018","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.jpet.2026.105005_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-006-9281-1","article-title":"The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells","volume":"101","author":"Brackenbury","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jpet.2026.105005_bib18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1113\/JP282306","article-title":"Sodium channels and the ionic microenvironment of breast tumours","volume":"601","author":"Leslie","year":"2023","journal-title":"J Physiol"},{"key":"10.1016\/j.jpet.2026.105005_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/19336950.2019.1666455","article-title":"Voltage gated sodium channels in cancer and their potential mechanisms of action","volume":"13","author":"Angus","year":"2019","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.jpet.2026.105005_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4161\/chan.2.6.7362","article-title":"Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine","volume":"2","author":"Rajamani","year":"2008","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.jpet.2026.105005_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-006-9485-4","article-title":"Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI","volume":"106","author":"Ouwerkerk","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jpet.2026.105005_bib22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1476-4598-13-264","article-title":"Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization","volume":"13","author":"Driffort","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jpet.2026.105005_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41391-019-0128-3","article-title":"Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate","volume":"22","author":"Bugan","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jpet.2026.105005_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3835(01)00547-X","article-title":"EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells","volume":"169","author":"Zhu","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jpet.2026.105005_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/ijms18020262","article-title":"Deguelin potentiates apoptotic activity of an EGFR tyrosine kinase inhibitor (AG1478) in PIK3CA-mutated head and neck squamous cell carcinoma","volume":"18","author":"Baba","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2026.105005_bib26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1349-7006.2010.01527.x","article-title":"Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast","volume":"101","author":"Kimura","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jpet.2026.105005_bib27","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.12659\/MSM.909901","article-title":"Inhibition of epidermal growth factor receptor (EGFR) reduces lipopolysaccharide (LPS)-induced activation and inflammatory cytokines in hepatic stellate cells in vitro","volume":"24","author":"Qian","year":"2018","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jpet.2026.105005_bib28","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/febs.16240","article-title":"EGFR is a pivotal player of the E2\/ER\u03b2 - mediated functional properties, aggressiveness, and stemness in triple-negative breast cancer cells","volume":"289","author":"Kyriakopoulou","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.jpet.2026.105005_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41388-021-02086-9","article-title":"EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers","volume":"41","author":"Cicek","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.jpet.2026.105005_bib30","article-title":"Triple-negative metaplastic breast carcinoma: association of epidermal growth factor receptor expression with prognostic parameters and clinical outcome","volume":"13","author":"Munawar","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jpet.2026.105005_bib31","first-page":"4939","article-title":"Functional expression of the voltage-gated Na(+)-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells","volume":"126","author":"Campbell","year":"2013","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jpet.2026.105005_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1186\/1471-2407-13-599","article-title":"The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer","volume":"13","author":"Huang","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jpet.2026.105005_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/0008-5472.CAN-08-3612","article-title":"Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis","volume":"69","author":"Ricono","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2026.105005_bib34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpet.2026.105005_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-005-9120-9","article-title":"Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells","volume":"9","author":"Hiscox","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jpet.2026.105005_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.14740\/wjon1518","article-title":"A ROS\/Akt\/NF-\u03baB signaling cascade mediates epidermal growth factor-induced epithelial-mesenchymal transition and invasion in human breast cancer cells","volume":"13","author":"Min","year":"2022","journal-title":"World J Oncol"},{"key":"10.1016\/j.jpet.2026.105005_bib37","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpet.2026.105005_bib38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2026.105005_bib39","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.yjmcc.2006.10.013","article-title":"Regulation of voltage-gated cardiac sodium current by epidermal growth factor receptor kinase in guinea pig ventricular myocytes","volume":"42","author":"Liu","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jpet.2026.105005_bib40","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0105","article-title":"Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation","volume":"369","author":"Fraser","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.jpet.2026.105005_bib41","first-page":"388","article-title":"Epidermal growth factor upregulates voltage-gated sodium channel\/Nav1.5 expression and human breast cancer cell invasion","volume":"31","author":"Pan","year":"2011","journal-title":"Basic Clin Med"},{"key":"10.1016\/j.jpet.2026.105005_bib42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.biocel.2009.11.021","article-title":"Protein kinase A and regulation of neonatal Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration","volume":"42","author":"Chioni","year":"2010","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jpet.2026.105005_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jcp.21289","article-title":"Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity","volume":"215","author":"Ding","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jpet.2026.105005_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1476-4598-6-76","article-title":"Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel","volume":"6","author":"Uysal-Onganer","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jpet.2026.105005_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2026.178857","article-title":"Studying synergistic anticancer effects of repurposed AT1B losartan with antidiabetics metformin, rosiglitazone in triple-negative breast cancer cells","volume":"1022","author":"Al-Mashhadani","year":"2026","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2026.105005_bib46","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7150\/jca.2.324","article-title":"Targeting EGFR in triple negative breast cancer","volume":"2","author":"Ueno","year":"2011","journal-title":"J Cancer"},{"key":"10.1016\/j.jpet.2026.105005_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025080","article-title":"Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer","volume":"6","author":"El Guerrab","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2026.105005_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/pcm-20-62","article-title":"Anti-proliferative and anti-migratory effects of EGFR and c-Met tyrosine kinase inhibitors in triple negative breast cancer cells","volume":"4","author":"Lefebvre","year":"2021","journal-title":"Precis Cancer Med"},{"key":"10.1016\/j.jpet.2026.105005_bib49","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.7150\/thno.57706","article-title":"EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652601205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:18:05Z","timestamp":1794561485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652601205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S002235652601205X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105005","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ranolazine inhibits invasiveness of human breast cancer cells in combination with a tyrosine kinase inhibitor: Dose-dependent synergy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"105005"}}